What are ovarian tumor markers

I believe that for patients diagnosed with ovarian tumors, the five markers for ovarian tumor detection will not be unfamiliar during the examination process, because modern medical technology will use these five markers to diagnose ovarian tumors in patients with ovarian tumors. Therefore, I think this kind of technical test should still be carried out in a professional tumor hospital.

Five markers of ovarian tumors

The five ovarian tumor markers include serum CA125, CA199, alpha-fetoprotein, CEA and ferritin. The combined detection of these five ovarian tumor markers also demonstrates high clinical value in the diagnosis and identification of ovarian tumor diseases. It also provides an accurate basis for clinical treatment.

In addition, in a medical discussion, it is believed that CA125 is the most widely used marker for ovarian malignant tumors in the current medical field. In patients with general malignant ovarian tumors, the CA125 index has exceeded 80%. However, if CA125 is used alone as a criterion for judging ovarian malignant tumors, it is obviously not scientific and comprehensive enough. This also requires a comprehensive clinical analysis. Because CA199 is an oligosaccharide antigen, it is also significantly different from the combined test.

AFP is specific for the endodermal sinus inside the ovary and has diagnostic value. There are also significant differences in combined detection. CEA is a nonspecific marker of malignant tumors. It is an acidic glycoprotein. The last SF is also a protein that resides in the village and is related to the progression of the disease. If the malignant tumor cells grow rapidly, they will secrete more proteins.

In summary, if any of the five markers of ovarian tumors is examined independently, it is not comprehensive and rigorous enough. Only through the joint detection of the five markers can the shortcomings of each be made up. Therefore, the five markers of ovarian tumors still have a very high clinical value in diagnosing ovarian malignant tumor myopathy.